DoD Tuberous Sclerosis Complex, Idea Development Award | HT942524TSCRPIDA

Opportunity Information: Apply for HT942524TSCRPIDA

The Department of Defense, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is offering the Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) under funding opportunity number HT942524TSCRPIDA (CFDA 12.420). This is a discretionary grant in the science, technology, and research and development category, and eligibility is listed as unrestricted, meaning a broad range of applicant organizations and investigators may apply if they meet the program requirements. The original application closing date is August 1, 2024, and the program anticipates making about three awards. (The posted notice does not specify an award ceiling in the provided source text.)

The core purpose of the Idea Development Award is to push the field toward high-impact discoveries and open up new directions in tuberous sclerosis complex (TSC) research and, ultimately, improvements in patient care. The program is geared toward conceptually innovative projects rather than incremental next-step studies. Applicants are expected to propose research that could shift understanding, change existing assumptions, or approach long-standing problems in a genuinely new way. The mechanism is intentionally positioned to support ideas that carry some risk, as long as the potential payoff is high and the scientific reasoning is strong.

A central requirement is that the proposed project is built around a clear, well-formulated, and testable hypothesis. Even though the award is aimed at innovation, the application still needs to show solid scientific grounding. That is why preliminary data are not optional here: applicants must include unpublished findings from the PI’s lab or from named collaborators, and/or leverage relevant published data that directly support the feasibility and rationale of the proposed work in TSC. In other words, the program wants bold ideas, but not speculative ones that lack evidence or a credible path to testing.

Reviewers will focus heavily on two big themes: impact and innovation. For impact, applicants must spell out both the short-term and long-term significance of the work. A strong application will explain what concrete advances could come from the project if it succeeds, such as meaningful progress in understanding TSC biology, identifying new therapeutic strategies, improving diagnosis or management, or otherwise affecting real-world patient outcomes. For innovation, the expectation is that the project does more than refine existing approaches. The opportunity explicitly notes that research viewed as merely an incremental advance to the next logical step will not meet the intent. Instead, competitive projects should introduce a new paradigm, challenge a prevailing paradigm, or reframe a known problem through a different lens, potentially using high-risk, high-reward approaches when justified.

The opportunity also includes a New-to-the-Field Investigator (NFI) option, reflecting a strong interest in bringing new talent and new perspectives into TSC research. This track is designed both for early-stage independent investigators who are still building their TSC research careers and for established researchers from other fields who want to transition into TSC. Importantly, NFI applications compete separately from those submitted by established TSC investigators under the regular IDA track. While the program encourages independence, it also emphasizes the value of collaboration for NFI applicants. New-to-the-field PIs are strongly encouraged to partner with investigators who have demonstrated TSC expertise or other key capabilities, supported by a track record of funding and publications, to strengthen the scientific foundation and increase the likelihood of success. The notice references an Eligibility Statement (Attachment 8) for the specific NFI criteria and documentation expectations.

Overall, this funding opportunity is best suited for applicants who can pair an ambitious, creatively framed TSC research question with credible preliminary evidence and a rigorous experimental plan, and who can clearly argue how success would move the field forward in a substantial way rather than by small increments.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Tuberous Sclerosis Complex, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-04-19.
• Applicants must submit their applications by 2024-08-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524TSCRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: